MIR501

Summary

MIR501 (microRNA 501, HGNC:32135) is a microRNA gene on chromosome Xp11.23.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 574503 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32135
Approved symbol	MIR501
Name	microRNA 501
Location	Xp11.23
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-501
Ensembl gene	ENSG00000211538
Ensembl biotype	miRNA
Entrez	574503
RNAcentral	URS000075D7AB — miRNA, 84 nt, 6 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000390204

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000390204 — 1 exons

Exon	Start	End
ENSE00001808144	50009722	50009805

Expression profiles

Bgee: expression breadth broad, 19 present calls, max score 81.23.

Top tissues by expression

19 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	81.23	gold quality
intestine	UBERON:0000160	77.73	gold quality
monocyte	CL:0000576	75.85	gold quality
kidney	UBERON:0002113	75.68	gold quality
stomach	UBERON:0000945	73.82	gold quality
colon	UBERON:0001155	72.29	gold quality
islet of Langerhans	UBERON:0000006	70.85	gold quality
body of stomach	UBERON:0001161	68.75	gold quality
left adrenal gland cortex	UBERON:0035825	67.90	gold quality
esophagus mucosa	UBERON:0002469	67.50	gold quality
vagina	UBERON:0000996	64.14	gold quality
transverse colon	UBERON:0001157	64.11	gold quality
lower esophagus muscularis layer	UBERON:0035833	63.97	gold quality
skin of leg	UBERON:0001511	63.81	gold quality
skin of abdomen	UBERON:0001416	63.77	gold quality
subcutaneous adipose tissue	UBERON:0002190	62.55	gold quality
right hemisphere of cerebellum	UBERON:0014890	61.71	gold quality
omental fat pad	UBERON:0010414	61.38	gold quality
tibial artery	UBERON:0007610	61.21	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.33

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 29)

• knockdown of HBXIP rescued the inhibition of HBV that occurred after the loss of miR-501 in HepG2.2.15 cells, suggesting that miR-501 induced HBV replication partially by targeting HBXIP. (PMID:23266610)
• MiR-501-5p may play an important role in the development of hepatocellular carcinoma by promoting cell proliferation, and indicates that miR-501-5p may represent a novel therapeutic target (PMID:25917358)
• Single nucleotide polymorphisms (rs112489955) located in miR-501 is associated with the risk of hepatocellular carcinoma in a Chinese Han population. (PMID:27310251)
• Study has revealed that miR-501-5p upregulation plays an important role in gastric cancer progression through the activation of Wnt/ beta-catenin signaling. (PMID:27846906)
• High miR501 expression is associated with recurrence in pancreatic head cancer. (PMID:28122349)
• the overexpression of miR501-5p stimulates cell proliferation in kidney cells by the inhibition of p53 function in a mechanism driven by mTOR signaling. (PMID:29323708)
• A potential BSG regulator, miR-501-3p, was identified by miRNA sequencing and Dual-Luciferase assay, but was not proven to regulate the expression of BSG in K562 cells. (PMID:29707789)
• miR-501-3p suppresses metastasis and progression of hepatocellular carcinoma through targeting LIN7A. (PMID:29749382)
• restoration of MYCN reversed the effects of miR5013p in cisplatinresistant glioma cells. In conclusion, these results suggested that miR5013p may serve a promising marker for cisplatin resistance. (PMID:30221699)
• miR-501-3p represses the growth of prostate cancer cells. CREPT is identified as a target gene of miR-501-3p. miR-501-3p regulates cyclin D1 and cell growth by targeting CREPT. (PMID:30621914)
• miR-501 ectopic expression promoted HCC cell invasion and epithelial-mesenchymal transition (EMT), while low expression present the opposite results. (PMID:30877624)
• High miR501 expression is associated with osteosarcoma. (PMID:31111286)
• MiR-501 knockdown or BH3-like motif-containing protein, cell death inducer (BLID) overexpression could reverse the effects of ADR Exo on recipient cells. (PMID:31173853)
• Highly expressed miR-501 was observed in pancreatic ductal adenocarcinoma (PDAC) tissues and tumor-associated macrophage (TAM)-derived exosomes. M2 macrophage-derived exosomal miR-501 inhibits tumor suppressor TGFBR3 gene and facilitates the development of PDAC by activating the TGF-beta signaling pathway (PMID:31307515)
• Inhibition of KHSRP sensitizes colorectal cancer to 5-fluoruracil through miR-501-5p-mediated ERRFI1 mRNA degradation. (PMID:31313286)
• Results demonstrated that miR501 was overexpressed in colorectal cancer (CRC) tissues compared to the adjacent normal tissues. Its downregulation inhibited cell proliferation and sphere formation, while it induced cell cycle arrest at the G1 phase. Study identified miR501 as a novel regulator of Wnt/betacatenin signaling in CRC via targeting APC, suggesting that miR501 may act as a novel oncogenic miRNA in CRC. (PMID:31364752)
• microRNA-501-5p promotes cell proliferation and migration in gastric cancer by downregulating LPAR1. (PMID:31746031)
• MiR-501-3p functions as a tumor suppressor in non-small cell lung cancer by downregulating RAP1A. (PMID:31805277)
• LINC00452 promotes ovarian carcinogenesis through increasing ROCK1 by sponging miR-501-3p and suppressing ubiquitin-mediated degradation. (PMID:33168781)
• MiR-501-3p promotes osteosarcoma cell proliferation, migration and invasion by targeting BCL7A. (PMID:33415690)
• Osteosarcoma-derived exosomal miR-501-3p promotes osteoclastogenesis and aggravates bone loss. (PMID:33529755)
• MiR-501 promotes tumor proliferation and metastasis by targeting HOXD10 in endometrial cancer. (PMID:34022794)
• Exercise as a model to identify microRNAs linked to human cognition: a role for microRNA-409 and microRNA-501. (PMID:34625536)
• Importance of miR-141-5p and miR-501-5P expression in patients with HBV infection. (PMID:34933711)
• MiR-501-5p alleviates cardiac dysfunction in septic patients through targeting NR4A3 to prevent its binding with Bcl-2. (PMID:35230891)
• Expression Profiles of Exosomal MicroRNAs Derived from Cerebrospinal Fluid in Patients with Congenital Hydrocephalus Determined by MicroRNA Sequencing. (PMID:35371347)
• MicroRNA-501-3p targeting TM4SF1 facilitates tumor-related behaviors of gastric cancer cells via EMT signaling pathway. (PMID:36274500)
• microRNA-501 controls myogenin[+]/CD74[+] myogenic progenitor cells during muscle regeneration. (PMID:36907509)
• MicroRNA, miR-501 regulate the V(D)J recombination in B cells. (PMID:38084601)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir501	ENSMUSG00000076251

Paralogs (3): MIR500A (ENSG00000207785), MIR500B (ENSG00000239057), MIR502 (ENSG00000272080)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.